Soleno Therapeutics shares are trading higher after the company announced the FDA review division has determined an advisory committee is not needed for the NDA for DCCR extended-release tablets.
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics shares rose after the FDA decided that an advisory committee is not needed for the NDA review of DCCR extended-release tablets.
October 08, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soleno Therapeutics' stock price increased following the FDA's decision to forgo an advisory committee for the NDA review of its DCCR extended-release tablets.
The FDA's decision to not require an advisory committee suggests a smoother and potentially faster approval process for Soleno's DCCR tablets, which is seen as a positive development by investors, leading to a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100